ClinicalTrials.gg
CompletedNCT03095352Updated Dec 22, 2025Results posted

Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease

A Phase 2 interventional study of Pembrolizumab and Carboplatin in Breast Cancer and Chest Wall Disease, sponsored by Laura Huppert, MD, BA. Completed at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-22.

Sponsored by Laura Huppert, MD, BA · Phase 2, Interventional, and Treatment

How we know · 7 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
76
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 85 studies testing pembrolizumab in Breast Neoplasms — 22 open to participants now, 45 under way, 8 of them phase 3. pembrolizumab · Breast Neoplasms.

Enrollment
26th of 85
76 · median 44
Started
2017
with 15 others
Phase 2
56 of 85
13 open now
Registered
27th of 85
by date

Among the 85 studies testing pembrolizumab in Breast Neoplasms, this one is the 26th largest by enrollment, is one of 16 that started in 2017, is one of 56 in phase 2, and was the 27th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

22 of the 85 studies testing pembrolizumab in Breast Neoplasms are open now, in 11 countries. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About pembrolizumab

pembrolizumab: first FDA approval 2014 (KEYTRUDA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 85 studies testing pembrolizumab in Breast Neoplasms, or all of them as a file.
02

Study summary

This is a phase II multicenter study including breast cancer patients with chest wall disease that is hormone resistant (estrogen receptor (ER) positive/progesterone receptor (PR) positive/human epidermal growth factor receptor 2 (HER2) negative breast cancer with progressive disease on 2 prior lines of hormonal therapy) or triple negative (ER negative/PR negative/HER2 negative, TNBC).

A companion translational study is operating concurrently with the study described above. In this study, biomarker research to be performed on tumor biopsies and peripheral blood samples will be performed to explore the immunologic and genomic mechanism of action underlying treatment with pembrolizumab and carboplatin versus carboplatin alone. This protocol includes tissue and blood correlative exploratory endpoints including changes in tumor PD-L1 (programmed death ligand 1) gene expression, tumor and peripheral blood immune composition and cytokine expression, plasma tumor DNA, circulating tumor cells, and tumor myelocytomatosis (MYC) oncogene expression using tumor biopsy and peripheral blood testing before and after treatment; correlations with these markers and disease control rate will be assessed.

Read the detailed description

PRIMARY OBJECTIVE:

I. To determine the disease control rate (including complete response (CR), partial response (PR) and stable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 at 18 weeks of treatment in breast cancer patients with chest wall disease treated with pembrolizumab and carboplatin or carboplatin alone.

SECONDARY OBJECTIVES:

I. To determine the disease control rate (including CR, PR and stable disease as defined by Immune-related Response Evaluation Criteria In Solid Tumors (irRECIST) at 18 weeks of treatment in breast cancer participants with chest wall disease treated with pembrolizumab and carboplatin or carboplatin alone.

II. To determine progression free survival (PFS) in participants treated with pembrolizumab and carboplatin vs. carboplatin alone.

III. To determine the toxicity of pembrolizumab and carboplatin vs. carboplatin alone.

IV. To determine 18 week disease control rate (DCR) based on tumor programmed death-ligand 1 (PD-L1) expression via immunohistochemistry.

V. To determine the overall response rate (ORR) of participants treated with pembrolizumab and carboplatin vs. carboplatin alone.

OUTLINE:

Participants will be enrolled at Translational Breast Cancer Research Consortium (TBCRC) sites and will be randomized 2:1 to receive treatment with pembrolizumab and carboplatin (n=56, Arm A) or carboplatin alone (n=28, Arm B) until documented disease progression.

Participants randomized to Arm B may cross-over after documented disease progression to pembrolizumab with or without carboplatin at investigator's discretion. Participants in Arm A will be treated with combination pembrolizumab and carboplatin followed by maintenance pembrolizumab if stable or responding disease.

Participants in Arm B will be treated with carboplatin only until disease progression, whereupon they may crossover to receive pembrolizumab with or without carboplatin at investigator's discretion (Arm Bx). After the end of treatment, each subject will be followed for 30 days for adverse event monitoring (serious adverse events will be collected for 90 days after the end of treatment. Participants who discontinue for reasons other than progressive disease will have post-treatment follow-up for disease status until disease progression, initiating a non-study cancer treatment, withdrawing consent, becoming lost to follow-up, or death.

03

Conditions studied

  • Breast Cancer
  • Chest Wall Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Advanced breast cancer with locally recurrent chest wall disease not amenable to surgical excision with curative intent.

    1. Distant sites of disease are allowed
    2. Prior radiation to the chest wall is not required
  2. The following disease subtypes are eligible:

    1. Triple negative disease (defined as ER \< 10%, PR \< 10%, negative)
    2. Hormone receptor positive, HER2 negative disease with evidence of progression on at least two prior lines of hormone therapy, unless, per treating investigator's judgement, is not considered a candidate for further endocrine therapy
    3. HER2 positive disease with evidence of disease progression on trastuzumab, pertuzumab, Trastuzumab emtansine (T-DM1), and oral tyrosine kinase inhibitor unless with no other HER2 targeted therapy options available. Patients in this category will be classified by ER status

      • confirmed HER2+ breast carcinoma, with HER2+ defined by in situ hybridization (ISH) or fluorescence in situ hybridization (FISH) or immunohistochemistry (IHC) methodology using standard criteria.
      • Cardiac function must be determined within 4 weeks of study entry to be >= institutional lower limit of normal (LLN) using echo or multiple gated acquisition scan ().
  3. Any number of are allowed. a Prior platinum based therapy is allowed in the following settings:

    • Treatment in the and/or adjuvant setting without clear progression of disease.
    • Treatment in the setting without clear progression of disease. b Neo/adjuvant treatment with a is allowed if the last treatment was at least 12 months from the diagnosis of metastatic disease.
  4. At least two weeks from last systemic therapy for breast cancer, with recovery of all treatment related toxicity to grade 1 or less. Subjects with \<= Grade 2 neuropathy are an exception to this criterion.
  5. At least two weeks from last radiation therapy, with recovery of all treatment related toxicity to grade 1 or less (excluding alopecia).
  6. Prior CNS disease is allowed if stable for at least one month since whole brain radiation therapy, and 2 weeks since stereotactic radiotherapy, and not requiring . Patients whose CNS disease was surgically treated may be enrolled if stable for at least one month, and not requiring steroids.
  7. Able to provide tissue from a newly obtained core or excisional of a chest wall tumor lesion. Newly-obtained is defined as a specimen any time after the last systemic or local therapy utilized to treat the disease. Subjects for whom newly-obtained samples cannot be provided (e.g. inaccessible or subject safety concern) may submit an archived specimen only upon agreement from the Sponsor.
  8. Willing and able to provide written .
  9. Greater than or equal to 18 years of age on day of signing informed consent.
  10. (ECOG) performance status of less than or equal to 2.
  11. Adequate organ function as defined below within 10 business days of treatment initiation:

    • (ANC) >=1,000 /microliter (mcL)
    • >=100,000 / mcL
    • ≥9 g/dL or ≥5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)
    • Serum creatinine OR Measured or calculated* ( can also be used in place of creatinine or CrCl) \<=1.5 X (ULN) OR >=60 mL/min for subject with creatinine levels > 1.5 X institutional ULN. Creatinine clearance should be calculated per institutional standard.
    • Serum total ≤ 1.5 X ULN OR Direct bilirubin \<= ULN for subjects with total bilirubin levels > 1.5 ULN
    • (AST) (SGOT) and Alanine aminotransferase (ALT) (SGPT) ≤ 2.5 X ULN OR ≤ 5 X ULN for subjects with liver metastases
    • Albumin >2.5 g/dL
    • (INR) or Prothrombin Time (PT) \<=1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants
    • Activated Partial Thromboplastin Time (aPTT) \<=1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants
  12. Female subjects of should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
  13. Female subjects of childbearing potential should be willing to use an acceptable form of or be surgically sterile, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication (Reference Section 5.7.2). Subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year.
  14. Male subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy.

Exclusion criteria

Exclusion Criteria:

  1. Treatment with an agent within 4 weeks of the first dose of treatment.
  2. A diagnosis of immunodeficiency or is currently receiving systemic therapy at any dose or is receiving any other form of therapy. Steroid therapy is not allowed within 7 days prior to the first dose of trial treatment. However, topical and intranasal corticosteroids are allowed, and not an exclusion for participation.
  3. Known active TB (Bacillus Tuberculosis). Patients with a distant history of tuberculosis that was appropriately treated and have no evidence of active infection are eligible to participate. Patients with a history of latent tuberculosis that was appropriately treated are also eligible to participate.
  4. to pembrolizumab or any of its .
  5. Hypersensitivity to carboplatin or cisplatin
  6. Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to a previously administered agent.

    • Note: Subjects with ≤ Grade 2 neuropathy are an exception to this criterion.
    • Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy.
  7. Has a known additional that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer.
  8. Has known active central nervous system (CNS) and/or carcinomatous meningitis.
  9. Has active disease that has required systemic treatment in the past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
  10. Has a history of (non-infectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/ interstitial lung disease
  11. Has an active infection requiring systemic therapy.
  12. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
  13. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
  14. Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment.
  15. Prior therapy in the metastatic setting.
  16. Has a known history of (HIV) (HIV 1/2 antibodies).
  17. Has known active virus (HBV) [e.g., hepatitis B surface antigen (HBsAg) reactive] or virus (HCV) [e.g., HCV ribonucleic acid (RNA), [qualitative] is detected].
  18. Has received a or live-attenuated vaccine within 30 days prior to the first dose of study drug. Administration of killed vaccines is allowed.
Terms in these criteria, in plain language(33)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
76 participants (actual)

Study arms

  • Experimental
    Arm A: Pembrolizumab + Carboplatin

    Participants receive carboplatin intravenously (IV) and pembrolizumab IV over 30 minutes on day 1. Participants who are HER2+ also receive trastuzumab IV every 3 weeks. Treatment repeats every 3 weeks for a least 6 courses in the absence of disease progression or unacceptable toxicity. After completion of 6 cycles of carboplatin and pembrolizumab, participants with stable or responding disease receive pembrolizumab monotherapy on day 1 of each cycle. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.

    Biological: Pembrolizumab · Drug: Carboplatin · Biological: Trastuzumab

  • Experimental
    Arm B: Carboplatin Monotherapy

    Participants receive carboplatin on day 1. Patients who are HER2+ also receive trastuzumab IV every 3 weeks. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Participants with disease progression (PD) are eligible to receive pembrolizumab on day 1 of each cycle (crossover). Carboplatin may be continued or added back into the treatment regimen at the investigator's discretion. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.

    Drug: Carboplatin · Biological: Trastuzumab

Interventions

  • BiologicalPembrolizumab

    200 mg Given IV

    Also known as: Keytruda

  • Arm A: area under the curve (AUC) 5 IV every 3 weeks Arm B: AUC 5 IV every 3 weeks

    Also known as: Ribocarbo

  • BiologicalTrastuzumab

    For HER2+ patients: IV every 3 weeks using standard approved dosing

    Also known as: Herceptin

06

What researchers measure

Primary outcomes

  1. Disease Control Rate (DCR) at 18 Weeks

    The percentage of participants with Complete response (CR), Partial Response (PR), and stable disease (SD) as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 at 18 weeks of treatment in breast cancer patients with chest wall disease treated with pembrolizumab and carboplatin (Arm A) or carboplatin alone (Arm B) will be reported.

    Time frame: Up to 18 weeks

  2. Median Progression Free Survival (PFS) at 18 Weeks

    PFS is defined as the time in months from observed objective response to disease progression at week 18 and will be summarized using estimates by the Kaplan-Meier method in order to account for any censoring participants by enrolling treatment arms (Arm A and Arm B only)

    Time frame: Up to 18 weeks

Secondary outcomes

  1. DCR by Immune-related (ir) RECIST at 18 Weeks

    The percentage of participants with Complete response (CR), Partial Response (PR), and stable disease (SD) as defined by Immune-related Response Evaluation Criteria in Solid Tumors (irRECIST) at 18 weeks of treatment in breast cancer patients with chest wall disease treated with pembrolizumab and carboplatin (Arm A) or carboplatin alone (Arm B) and also based on PD-L1 expression

    Time frame: Up to 18 weeks

  2. Objective Response Rate (ORR)

    ORR will be presented as the percentage of participants with CR or PR as determined by RECIST criteria.

    Time frame: Up to 18 weeks

  3. Number of Participants With Treatment-related Adverse Events (AEs)

    Adverse events will be graded and recorded according to NCI CTCAE Version 4.0 up to 30 days after the last treatment. Grade 1 laboratory abnormalities and white blood cell differential abnormalities excluding neutrophils (i.e., lymphocytes, monocytes, basophils, etc.) did not need to be recorded as adverse events.

    Time frame: Up to 18 months

07

Results

Posted Dec 22, 2025

Participant flow

Treatment assigned at enrollment
Participant flow — Treatment assigned at enrollment
MilestoneArm A: Pembrolizumab + CarboplatinArm B: Carboplatin Monotherapy, then Pembrolizumab for participants who progress only
Started5224
Completed5124
Not completed10
Withdrew: Withdrawal by subject10
Patients who Progressed on Arm B
Participant flow — Patients who Progressed on Arm B
MilestoneArm A: Pembrolizumab + CarboplatinArm B: Carboplatin Monotherapy, then Pembrolizumab for participants who progress only
Started016
Completed016
Not completed00

Outcome measures

PrimaryDisease Control Rate (DCR) at 18 Weeks

The percentage of participants with Complete response (CR), Partial Response (PR), and stable disease (SD) as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 at 18 weeks of treatment in breast cancer patients with chest wall disease treated with pembrolizumab and carboplatin (Arm A) or carboplatin alone (Arm B) will be reported.

Time frame:
Up to 18 weeks
Reported as:
Number · percentage of participants
Disease Control Rate (DCR) at 18 Weeks
percentage of participantsArm A: Pembrolizumab + CarboplatinArm B: Carboplatin Monotherapy, then Pembrolizumab for participants who progress only
Disease Control Rate (DCR) at 18 Weeks2017
PrimaryMedian Progression Free Survival (PFS) at 18 Weeks

PFS is defined as the time in months from observed objective response to disease progression at week 18 and will be summarized using estimates by the Kaplan-Meier method in order to account for any censoring participants by enrolling treatment arms (Arm A and Arm B only)

Time frame:
Up to 18 weeks
Reported as:
Median · months
Median Progression Free Survival (PFS) at 18 Weeks
monthsArm A: Pembrolizumab + CarboplatinArm B: Carboplatin Monotherapy
Median Progression Free Survival (PFS) at 18 Weeks2.06 (1.38 to 3.12)2.63 (1.44 to 4.17)
SecondaryDCR by Immune-related (ir) RECIST at 18 Weeks

The percentage of participants with Complete response (CR), Partial Response (PR), and stable disease (SD) as defined by Immune-related Response Evaluation Criteria in Solid Tumors (irRECIST) at 18 weeks of treatment in breast cancer patients with chest wall disease treated with pembrolizumab and carboplatin (Arm A) or carboplatin alone (Arm B) and also based on PD-L1 expression

Time frame:
Up to 18 weeks
Reported as:
Number · percentage of participants
DCR by Immune-related (ir) RECIST at 18 Weeks
percentage of participantsArm A: Pembrolizumab + CarboplatinArm B: Carboplatin Monotherapy
DCR by Immune-related (ir) RECIST at 18 Weeks1817
SecondaryObjective Response Rate (ORR)

ORR will be presented as the percentage of participants with CR or PR as determined by RECIST criteria.

Time frame:
Up to 18 weeks
Reported as:
Number · percentage of participants
Objective Response Rate (ORR)
percentage of participantsArm A: Pembrolizumab + CarboplatinArm B: Carboplatin Monotherapy
Objective Response Rate (ORR)812.5
SecondaryNumber of Participants With Treatment-related Adverse Events (AEs)

Adverse events will be graded and recorded according to NCI CTCAE Version 4.0 up to 30 days after the last treatment. Grade 1 laboratory abnormalities and white blood cell differential abnormalities excluding neutrophils (i.e., lymphocytes, monocytes, basophils, etc.) did not need to be recorded as adverse events.

Time frame:
Up to 18 months
Reported as:
Count of participants · Participants
Number of Participants With Treatment-related Adverse Events (AEs)
ParticipantsArm A: Pembrolizumab + CarboplatinArm B: Carboplatin MonotherapyArm BX: Arm B Participants Who Progressed
Number of Participants With Treatment-related Adverse Events (AEs)33126

Adverse events

Collected over Up to 18 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A: Pembrolizumab + Carboplatin15/52 (28.8%)15/52 (28.8%)43/52 (82.7%)
Arm B: Carboplatin Monotherapy2/24 (8.3%)2/24 (8.3%)19/24 (79.2%)
Arm BX: Participants who progressed on Arm B4/16 (25%)4/16 (25%)12/16 (75%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventArm A: Pembrolizumab + CarboplatinArm B: Carboplatin MonotherapyArm BX: Participants who progressed on Arm B
DyspeneaRespiratory, thoracic and mediastinal disorders1/521/242/16
Febrile NeurtopeniaBlood and lymphatic system disorders0/520/241/16
StrokeNervous system disorders0/520/241/16
SepsisInfections and infestations3/520/240/16
ConstipationGastrointestinal disorders0/521/240/16
Urinary Tract InfectionInfections and infestations0/521/240/16
AnemiaBlood and lymphatic system disorders2/520/240/16
Platelet Count DecreasedInvestigations2/520/240/16
VertigoEar and labyrinth disorders1/520/240/16
Adrenal InsufficiencyEndocrine disorders1/520/240/16
Most frequent other events
Showing 10 of 40
Most frequent other events
EventArm A: Pembrolizumab + CarboplatinArm B: Carboplatin MonotherapyArm BX: Participants who progressed on Arm B
Neutrophil count decreasedInvestigations18/524/242/16
Platelet count decreasedInvestigations16/524/243/16
AnemiaBlood and lymphatic system disorders14/524/241/16
FatigueGeneral disorders13/521/243/16
HypertensionVascular disorders6/525/242/16
White blood cell decreasedInvestigations10/522/241/16
Lymphocyte count decreasedInvestigations9/522/240/16
HypothyroidismEndocrine disorders1/521/242/16
Alkaline phosphatase increasedInvestigations0/521/242/16
AnorexiaMetabolism and nutrition disorders3/520/242/16

Baseline characteristics

Age, Continuous
Age, Continuous(years)Arm A: Pembrolizumab + CarboplatinArm B: Carboplatin MonotherapyTotal
Mean55.19 ± 12.1159.62 ± 11.2256.59 ± 11.94
Sex: Female, Male
Sex: Female, Male(Participants)Arm A: Pembrolizumab + CarboplatinArm B: Carboplatin MonotherapyTotal
Female522476
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm A: Pembrolizumab + CarboplatinArm B: Carboplatin MonotherapyTotal
Hispanic or Latino235
Not Hispanic or Latino471865
Unknown or Not Reported336
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm A: Pembrolizumab + CarboplatinArm B: Carboplatin MonotherapyTotal
American Indian or Alaska Native000
Asian606
Native Hawaiian or Other Pacific Islander011
Black or African American347
White391352
More than one race000
Unknown or Not Reported4610
Region of Enrollment
Region of Enrollment(participants)Arm A: Pembrolizumab + CarboplatinArm B: Carboplatin MonotherapyTotal
United States522476
08

Study locations

7 sites
  • University of California, San Francisco
    San Francisco, California 94143, United States
  • Georgetown University Hospital
    Washington D.C., District of Columbia 20007, United States
  • University of Chicago Comprehensive Cancer Center
    Chicago, Illinois 60637, United States
  • Indiana University/Melvin and Bren Simon Cancer Center
    Indianapolis, Indiana 46202, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • University of Pittsburgh Cancer Institute
    Pittsburgh, Pennsylvania 15232, United States
  • Vanderbilt University/Ingram Cancer Center
    Nashville, Tennessee 37232, United States
09

References and documents

Publications

  • Disis ML. Immune regulation of cancer. J Clin Oncol. 2010 Oct 10;28(29):4531-8. doi: 10.1200/JCO.2009.27.2146. Epub 2010 Jun 1. PubMed 20516428 ↗
  • Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, Royal RE, Kammula U, White DE, Mavroukakis SA, Rogers LJ, Gracia GJ, Jones SA, Mangiameli DP, Pelletier MM, Gea-Banacloche J, Robinson MR, Berman DM, Filie AC, Abati A, Rosenberg SA. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005 Apr 1;23(10):2346-57. doi: 10.1200/JCO.2005.00.240. PubMed 15800326 ↗
  • Hunder NN, Wallen H, Cao J, Hendricks DW, Reilly JZ, Rodmyre R, Jungbluth A, Gnjatic S, Thompson JA, Yee C. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med. 2008 Jun 19;358(25):2698-703. doi: 10.1056/NEJMoa0800251. PubMed 18565862 ↗
  • Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol. 2005;23:515-48. doi: 10.1146/annurev.immunol.23.021704.115611. PubMed 15771580 ↗
  • Okazaki T, Maeda A, Nishimura H, Kurosaki T, Honjo T. PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13866-71. doi: 10.1073/pnas.231486598. Epub 2001 Nov 6. PubMed 11698646 ↗
  • Zhang X, Schwartz JC, Guo X, Bhatia S, Cao E, Lorenz M, Cammer M, Chen L, Zhang ZY, Edidin MA, Nathenson SG, Almo SC. Structural and functional analysis of the costimulatory receptor programmed death-1. Immunity. 2004 Mar;20(3):337-47. doi: 10.1016/s1074-7613(04)00051-2. PubMed 15030777 ↗
  • Chemnitz JM, Parry RV, Nichols KE, June CH, Riley JL. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol. 2004 Jul 15;173(2):945-54. doi: 10.4049/jimmunol.173.2.945. PubMed 15240681 ↗
  • Sheppard KA, Fitz LJ, Lee JM, Benander C, George JA, Wooters J, Qiu Y, Jussif JM, Carter LL, Wood CR, Chaudhary D. PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta. FEBS Lett. 2004 Sep 10;574(1-3):37-41. doi: 10.1016/j.febslet.2004.07.083. PubMed 15358536 ↗
  • Riley JL. PD-1 signaling in primary T cells. Immunol Rev. 2009 May;229(1):114-25. doi: 10.1111/j.1600-065X.2009.00767.x. PubMed 19426218 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2017 to primary completion in Nov 2024, 86 months.

Results were first posted in Dec 2025, 1 year after primary completion.

Of 1,070 non-industry phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 89. This study's 86 months is above that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2017
First posted
Mar 29, 2017
StartActual
Sep 2, 2017
Primary completionActual
Nov 30, 2024
CompletionActual
Nov 30, 2024
Results first posted
Dec 22, 2025
Last update
Dec 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03095352
Lead sponsor
Laura Huppert, MD, BA
Collaborators
Mayo Clinic, Johns Hopkins University, Translational Breast Cancer Research Consortium, Massachusetts General Hospital, Merck Sharp & Dohme LLC
Responsible party
Laura Huppert, MD, BA (Assistant Clinical Professor, University of California, San Francisco) — Sponsor-investigator
First posted
Mar 29, 2017
Start date
Sep 2, 2017
Primary completion
Nov 30, 2024
Completion
Nov 30, 2024
Results posted
Dec 22, 2025
Last update
Dec 22, 2025

Study contacts

Laura Huppert, MD, BA
principal investigator · University of California, San Francisco
Neelima Vidula, MD
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pembrolizumab

Start the discussion